MUC1过表达预示非小细胞肺癌患者的生存预后更差：一项更新的荟萃分析证据
MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis.
作者信息
Huang Xing, Sun Qi, Chen Chen, Zhang Yi, Kang Xin, Zhang Jing-Yuan, Ma Da-Wei, Xia Lei, Xu Lin, Xu Xin-Yu, Ren Bin-Hui
机构信息
Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China.
Department of Cardiothoracic Surgery, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu, China.
出版信息
Oncotarget. 2017 Aug 3;8(52):90315-90326. doi: 10.18632/oncotarget.19861. eCollection 2017 Oct 27.
BACKGROUND
Previous studies on the prognostic role of MUC1 expression in non-small cell lung cancer (NSCLC) remain controversial. We conducted a meta-analysis to appraise the clinicopathological and prognostic effect of MUC1 in NSCLC patients.
MATERIALS AND METHODS
Searches of PubMed, EMBASE and CNKI (Chinese National Knowledge Infrastructure) were conducted and relevant studies were extracted. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (CIs) were used to estimate effects. Heterogeneity among studies and publication bias were also evaluated.
RESULTS
A total of 15 studies with 1,682 patients were included in this meta-analysis. The pooled HRs indicated that elevated MUC1 expression was associated with poorer overall survival (HR = 2.12, 95% CI: 1.47-3.05; < 0.001) and progression-free survival (HR = 2.00, 95% CI: 1.53-2.62; < 0.001) in patients with NSCLC. Significant associations were also found in patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (HR = 3.16, 95% CI: 2.21-4.52, < 0.001) and with a platinum-based regimen (HR = 4.35, 95% CI: 2.45-7.72, < 0.001). Additionally, MUC1 overexpression was significantly associated with performance status (OR = 2.32, 95% CI: 1.13-4.73, = 0.021).
CONCLUSIONS
MUC1 could be a valuable biomarker of the prognoses of NSCLC patients.
背景
先前关于MUC1表达在非小细胞肺癌（NSCLC）中预后作用的研究仍存在争议。我们进行了一项荟萃分析，以评估MUC1在NSCLC患者中的临床病理及预后影响。
材料与方法
检索了PubMed、EMBASE和中国知网（CNKI），并提取了相关研究。采用合并风险比（HR）或比值比（OR）及95%置信区间（CI）来估计效应。同时评估了研究间的异质性和发表偏倚。
结果
本荟萃分析共纳入15项研究，涉及1682例患者。合并HR表明，MUC1表达升高与NSCLC患者较差的总生存期（HR = 2.12，95% CI：1.47 - 3.05；P < 0.001）和无进展生存期（HR = 2.00，95% CI：1.53 - 2.62；P < 0.001）相关。在接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR - TKIs）治疗的患者（HR = 3.16，95% CI：2.21 - 4.52，P < 0.001）和接受铂类方案治疗的患者（HR = 4.35，95% CI：2.45 - 7.72，P < 0.001）中也发现了显著相关性。此外，MUC1过表达与体能状态显著相关（OR = 2.32，95% CI：1.13 - 4.73，P = 0.021）。
结论
MUC1可能是NSCLC患者预后的一个有价值的生物标志物。
Zotero 插件